Journal
CLINICAL CANCER RESEARCH
Volume 28, Issue 10, Pages 1993-1995Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-22-0201
Keywords
-
Categories
Funding
- Ministerio de Ciencia e Innovacion/Agencia estatal de investigacion (MICIN/AEI) [PID2020-112892RB]
- MICIN/AEI [SAF2017-83267-C2-1-R]
- FEDER Una manera de hacer Europa
- Fundacion de la Asociacion Espanola Contra el Cancer (AECC) [HR21-00083]
- Fundacion La Caixa
- Fundacion BBVA
- Instituto de Salud Carlos III - Fondos FEDER [2015 (JTC 2015), TRANSCAN456 2, TRS-2016-00000371]
- Gobierno de Navarra Proyecto LINTERNA [0011-1411-2020-000075]
- Miguel Servet I contract from Instituto de Salud Carlos III (ISCIII)
- Fondo Social Europeo (FSE) Investing in your future
- Predoctoral de formacion en investigacion en salud fellowship from ISCIII [FI20/00058]
- Spanish Association Against Cancer's (AECC) -Clinico Junior AECC 2020 [CLJUN20011EGUR]
Ask authors/readers for more resources
Ovarian cancer often spreads within the peritoneal cavity as peritoneal carcinomatosis, allowing for targeted delivery of combination immunotherapy agents to maximize effectiveness and minimize systemic exposure and side effects.
Ovarian cancer is often limited to the peritoneal cavity in the form of peritoneal carcinomatosis. Peritoneal spreading offers the opportunity for locoregional delivery of combinations of immuno- therapy agents, maximizing bioavailability while potentially reduc-ing systemic exposure and side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
